These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 18084768)

  • 1. Volumetric high-frequency Doppler ultrasound enables the assessment of early antiangiogenic therapy effects on tumor xenografts in nude mice.
    Jugold M; Palmowski M; Huppert J; Woenne EC; Mueller MM; Semmler W; Kiessling F
    Eur Radiol; 2008 Apr; 18(4):753-8. PubMed ID: 18084768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vessel fractions in tumor xenografts depicted by flow- or contrast-sensitive three-dimensional high-frequency Doppler ultrasound respond differently to antiangiogenic treatment.
    Palmowski M; Huppert J; Hauff P; Reinhardt M; Schreiner K; Socher MA; Hallscheidt P; Kauffmann GW; Semmler W; Kiessling F
    Cancer Res; 2008 Sep; 68(17):7042-9. PubMed ID: 18757418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitive noninvasive monitoring of tumor perfusion during antiangiogenic therapy by intermittent bolus-contrast power Doppler sonography.
    Krix M; Kiessling F; Vosseler S; Farhan N; Mueller MM; Bohlen P; Fusenig NE; Delorme S
    Cancer Res; 2003 Dec; 63(23):8264-70. PubMed ID: 14678984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Squamous Cell Carcinoma Xenografts: Use of VEGFR2-targeted Microbubbles for Combined Functional and Molecular US to Monitor Antiangiogenic Therapy Effects.
    Baetke SC; Rix A; Tranquart F; Schneider R; Lammers T; Kiessling F; Lederle W
    Radiology; 2016 Feb; 278(2):430-40. PubMed ID: 26313618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of high frequency ultrasound methods and contrast agents for characterising tumor response to anti-angiogenic treatment.
    Rix A; Lederle W; Siepmann M; Fokong S; Behrendt FF; Bzyl J; Grouls C; Kiessling F; Palmowski M
    Eur J Radiol; 2012 Oct; 81(10):2710-6. PubMed ID: 22093958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101.
    Kiessling F; Farhan N; Lichy MP; Vosseler S; Heilmann M; Krix M; Bohlen P; Miller DW; Mueller MM; Semmler W; Fusenig NE; Delorme S
    Neoplasia; 2004; 6(3):213-23. PubMed ID: 15153333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular profiling of angiogenesis with targeted ultrasound imaging: early assessment of antiangiogenic therapy effects.
    Palmowski M; Huppert J; Ladewig G; Hauff P; Reinhardt M; Mueller MM; Woenne EC; Jenne JW; Maurer M; Kauffmann GW; Semmler W; Kiessling F
    Mol Cancer Ther; 2008 Jan; 7(1):101-9. PubMed ID: 18202013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring Dual VEGF Inhibition in Human Pancreatic Tumor Xenografts With Dynamic Contrast-Enhanced Ultrasound.
    Lamuraglia M; Barrois G; Le Guillou-Buffello D; Santin M; Kerbol A; Comperat E; Coron A; Lucidarme O; Bridal SL
    Technol Cancer Res Treat; 2020; 19():1533033819886896. PubMed ID: 32065066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia.
    Franco M; Man S; Chen L; Emmenegger U; Shaked Y; Cheung AM; Brown AS; Hicklin DJ; Foster FS; Kerbel RS
    Cancer Res; 2006 Apr; 66(7):3639-48. PubMed ID: 16585189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human tumor xenografts recurring after radiotherapy are more sensitive to anti-vascular endothelial growth factor receptor-2 treatment than treatment-naive tumors.
    Kozin SV; Winkler F; Garkavtsev I; Hicklin DJ; Jain RK; Boucher Y
    Cancer Res; 2007 Jun; 67(11):5076-82. PubMed ID: 17545583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade.
    Li J; Huang S; Armstrong EA; Fowler JF; Harari PM
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1477-85. PubMed ID: 16029810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-dimensional ultrasound molecular imaging of angiogenesis in colon cancer using a clinical matrix array ultrasound transducer.
    Wang H; Kaneko OF; Tian L; Hristov D; Willmann JK
    Invest Radiol; 2015 May; 50(5):322-9. PubMed ID: 25575176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors.
    Folkins C; Man S; Xu P; Shaked Y; Hicklin DJ; Kerbel RS
    Cancer Res; 2007 Apr; 67(8):3560-4. PubMed ID: 17440065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intra-Animal Comparison between Three-dimensional Molecularly Targeted US and Three-dimensional Dynamic Contrast-enhanced US for Early Antiangiogenic Treatment Assessment in Colon Cancer.
    Wang H; Lutz AM; Hristov D; Tian L; Willmann JK
    Radiology; 2017 Feb; 282(2):443-452. PubMed ID: 27490690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.
    Davis DW; Inoue K; Dinney CP; Hicklin DJ; Abbruzzese JL; McConkey DJ
    Cancer Res; 2004 Jul; 64(13):4601-10. PubMed ID: 15231672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of early antiangiogenic effects in human colon adenocarcinoma xenografts: in vivo changes of tumor blood volume in response to experimental VEGFR tyrosine kinase inhibitor.
    Kim YR; Yudina A; Figueiredo J; Reichardt W; Hu-Lowe D; Petrovsky A; Kang HW; Torres D; Mahmood U; Weissleder R; Bogdanov AA
    Cancer Res; 2005 Oct; 65(20):9253-60. PubMed ID: 16230386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic assessment of antiangiogenic therapy by monitoring both tumoral vascularization and tissue degeneration.
    Magnon C; Galaup A; Rouffiac V; Opolon P; Connault E; Rosé M; Perricaudet M; Roche A; Germain S; Griscelli F; Lassau N
    Gene Ther; 2007 Jan; 14(2):108-17. PubMed ID: 16943854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.
    Drevs J; Hofmann I; Hugenschmidt H; Wittig C; Madjar H; Müller M; Wood J; Martiny-Baron G; Unger C; Marmé D
    Cancer Res; 2000 Sep; 60(17):4819-24. PubMed ID: 10987292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultrasound-targeted microbubble destruction improved the antiangiogenic effect of Endostar in triple-negative breast carcinoma xenografts.
    Jing Y; Xiu-Juan Z; Hong-Jiao C; Zhi-Kui C; Qing-Fu Q; En-Sheng X; Li-Wu L
    J Cancer Res Clin Oncol; 2019 May; 145(5):1191-1200. PubMed ID: 30805775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.